GSM Affects Up to 87% of Postmenopausal Women — and Most Suffer in Silence

Genitourinary syndrome of menopause (GSM) describes the constellation of vulvovaginal, urinary, and sexual symptoms that result from declining estrogen and androgen levels during and after the menopause transition. Published in Frontiers in Reproductive Health, this review consolidates the epidemiology and clinical presentation of a condition that affects between 14% and 87% of postmenopausal women, depending on the population studied and how symptoms are assessed. Vaginal dryness and dyspareunia are the most commonly reported symptoms, but GSM also includes urinary urgency, recurrent urinary tract infections, and vulvar irritation. Unlike vasomotor symptoms, which often diminish over time, GSM is progressive — it worsens without treatment and does not resolve on its own.

The standard of care for GSM is well-established: lubricants and moisturizers as first-line non-hormonal options, with local estrogen therapy considered the gold standard for persistent symptoms. Vaginal DHEA (prasterone) and oral ospemifene are additional options. Yet the review highlights a striking gap between prevalence and treatment — many women never raise these symptoms with their providers, and many providers do not ask. The stigma around genitourinary symptoms creates a silence that allows a treatable condition to progress unchecked. Newer therapies including energy-based devices lack long-term efficacy data, and the review notes the absence of evidence beyond one year for most GSM treatments.

Why This Matters

GSM is a textbook case of a condition that benefits from proactive monitoring. Because it is progressive and because women frequently do not volunteer these symptoms, structured symptom tracking that specifically asks about genitourinary health can surface problems that would otherwise go unaddressed for years. When a platform includes GSM-specific domains — dryness, urinary symptoms, sexual function — and tracks them over time, it creates a record that normalizes these symptoms as part of the clinical picture and gives providers a clear signal to intervene. The alternative is silence, progression, and diminished quality of life — all of it preventable with a conversation that the data can start.